RT Journal Article
SR Electronic
T1 Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2020.03.31.017889
DO 10.1101/2020.03.31.017889
A1 Andrés Pizzorno
A1 Blandine Padey
A1 Thomas Julien
A1 Sophie Trouillet-Assant
A1 Aurélien Traversier
A1 Elisabeth Errazuriz-Cerda
A1 Julien Fouret
A1 Julia Dubois
A1 Alexandre Gaymard
A1 François-Xavier Lescure
A1 Victoria Dulière
A1 Pauline Brun
A1 Samuel Constant
A1 Julien Poissy
A1 Bruno Lina
A1 Yazdan Yazdanpanah
A1 Olivier Terrier
A1 Manuel Rosa-Calatrava
YR 2020
UL http://biorxiv.org/content/early/2020/04/02/2020.03.31.017889.abstract
AB In the current COVID-19 pandemic context, proposing and validating effective treatments represents a major challenge. However, the lack of biologically relevant pre-clinical experimental models of SARS-CoV-2 infection as a complement of classic cell lines represents a major barrier for scientific and medical progress. Here, we advantageously used human reconstituted airway epithelial models of nasal or bronchial origin to characterize viral infection kinetics, tissue-level remodeling of the cellular ultrastructure and transcriptional immune signatures induced by SARS-CoV-2. Our results underline the relevance of this model for the preclinical evaluation of antiviral candidates. Foremost, we provide evidence on the antiviral efficacy of remdesivir and the therapeutic potential of the remdesivir-diltiazem combination as a rapidly available option to respond to the current unmet medical need imposed by COVID-19.One Sentence Summary New insights on SARS-CoV-2 biology and drug combination therapies against COVID-19.